How to Get Zepbound Covered: Sleep Apnea, Heart Disease, and the Diagnosis Route

The short answer

Your plan may refuse Zepbound "for weight loss" and still cover it for something else. Zepbound is FDA-approved for moderate-to-severe sleep apnea. Wegovy is approved to cut heart-attack and stroke risk in people with heart disease, and for a liver disease called MASH. A documented diagnosis, not your BMI alone, is often what gets a claim paid.

That is not a loophole. It is how pharmacy benefits are built. Many employer plans carve out "weight-loss drugs" as a category and never pay for them. The same molecule, prescribed for an FDA-approved medical indication, is a different claim. It gets judged against different criteria, and Medicare treats it differently too.

The catch is that the diagnosis has to be real and on paper. Nobody should be steered into a sleep study they do not need. But a lot of mothers do have one of these conditions and have never been tested. The tired, headachy woman who snores a little is the classic undiagnosed sleep apnea patient (we explain why in Zepbound for sleep apnea).

Why the diagnosis matters more than the number on the scale

Here is how each approved use maps to what a plan usually asks for. Requirements differ by insurer, so treat the right-hand column as the typical starting list, not a promise.

Sources: FDA approval announcements for sleep apnea¹, cardiovascular risk² and MASH³.

Notice what is missing: PCOS, prediabetes and insulin resistance. None of them is an FDA-approved indication for any of these drugs. A prescription built on PCOS alone is off-label, so a plan that excludes weight drugs usually has nothing else to approve it under. That does not mean the drugs don't help with PCOS (we weigh that evidence in Ozempic for PCOS). It means PCOS rarely unlocks coverage by itself.

Sleep apnea: the sleep study that unlocks Zepbound

If you snore, wake unrefreshed, get morning headaches or are exhausted out of proportion to your life, ask your doctor for a sleep study. Many are now done at home. The result that matters is the apnea-hypopnea index (AHI). An AHI of 15 or more events an hour is moderate, and 30 or more is severe. The Zepbound sleep apnea trials enrolled people with moderate-to-severe disease, and the approval covers that group.¹

On Medicare this route is unusually clear. In a March 2026 memo, CMS told Part D plans that people prescribed Zepbound for moderate-to-severe sleep apnea should keep getting coverage through Part D. Plans have to run their normal exception process for those requests.⁴

Heart disease: Wegovy's cardiovascular route

Wegovy's heart indication comes from the SELECT trial. That trial enrolled adults 45 and older who already had cardiovascular disease, a BMI of 27 or more and no diabetes.⁵ If you have had a heart attack, a stroke or a diagnosis of peripheral artery disease, the prescription can be written for risk reduction instead of weight. CMS lists this use among the ones that stay on Part D.⁴ For who was and wasn't in that trial, see the heart benefit, and who was in the room.

Most mothers in their thirties and forties will not qualify this way, and that is good news about their arteries. But if your own history includes a cardiac event, mention it at the appointment where the GLP-1 is discussed.

Medicare: the $50 bridge, and who it skips

Since July 1, 2026, Medicare has run a demonstration called the Medicare GLP-1 Bridge. It runs through December 31, 2027. It lets eligible Part D members get certain GLP-1s for weight management for $50 a month. On Lilly's side that means Zepbound KwikPen or Foundayo, for people with a BMI of 35 or more, or 27 or more with certain weight-related conditions.⁶ The bridge is only for weight management. If you have sleep apnea, MASH or type 2 diabetes, CMS says your Part D plan covers you instead, and a bridge request that names one of those diagnoses will be denied.⁴ Wegovy's own savings page also points Medicare members to a $50 option.⁷

What the prior-authorization letter needs

Most coverage, by any route, runs through prior authorization. Your prescriber's office does the submitting. Bringing this list to the appointment saves weeks:

If the answer is no, ask for the denial in writing with the exact criterion you failed. Then ask your prescriber about a formulary exception or a peer-to-peer call with the plan's reviewer. Commercial plans also owe you an internal appeal and, after that, an external review by an independent reviewer. A denial for missing paperwork is the most fixable kind.

When the card helps, and when cash is the answer

Once a plan covers the drug, the manufacturer savings cards do the rest. Lilly says commercially insured patients with Zepbound coverage may pay as little as $25 for a one- or three-month supply.⁸ Novo's card offers the same $25 floor for covered Wegovy, with savings capped at $100 a month.⁷ Neither card works with Medicare or Medicaid. We compare the cards with the free-drug programs in Zepbound and Wegovy savings cards vs patient assistance.

If none of it works, self-pay is the floor, and it is lower than it used to be. Zepbound bought through LillyDirect runs $299 a month at 2.5 mg, $399 at 5 mg and $449 at higher doses if you refill within 45 days; miss that window and the top doses cost $499 to $699.⁹ Wegovy pens from NovoCare cost $199 for two fills for new patients through December 31, 2026, then $349. The Wegovy pill is $149 to $299 by dose.⁷ TrumpRx lists the same brands, from $149 for the Wegovy pill to $299 for Zepbound.¹⁰

That fallback matters because insurance is no guarantee of affordability. In a KFF poll published in November 2025, 56% of GLP-1 users said the drugs were hard to afford. That included 55% of respondents who had insurance, and 27% of insured users said they paid the full cost themselves.¹¹ Compare insurance-friendly programs on our GLP-1 with insurance board, or the lowest cash prices on the cheapest GLP-1 board.